Silk Road Medical (SILK) was rated a new fundamental "buy" at sell-side firm B. Riley on Friday. The company is focused on reducing the risk of stroke and it has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a minimally invasive procedure that can clear blockages and open a narrowed carotid artery.
Let's check out the charts and indicators.
In this daily bar chart of SILK, below, I can see a mixed picture. Standing back from the chart shows me a broad sideways pattern the past 12 months. Looking closer to the chart I see a downtrend from early February. Prices trade below the declining 50-day simple moving average line and below the cresting slower-to-react 200-day moving average line. The trading volume histogram shows an increase in activity in March and this suggests increased investor interest.
The daily On-Balance-Volume (OBV) line shows uneven weakness from December as traders appear to have become more aggressive sellers. The Moving Average Convergence Divergence (MACD) oscillator is in a bearish alignment below the zero line but it has narrowed towards a potential cover shorts buy signal.



